Benzinga | Jul 29, 2021 04:42PM EDT

Ligand Pharmaceuticals Q2 Adj. EPS $1.63 Beats $1.34 Estimate, Sales $84.70M Beat $70.41M Estimate

Ligand Pharmaceuticals (NASDAQ:LGND) reported quarterly earnings of $1.63 per share which beat the analyst consensus estimate of $1.34 by 21.64 percent. This is a 63 percent increase over earnings of $1.00 per share from the same period last year. The company reported quarterly sales of $84.70 million which beat the analyst consensus estimate of $70.41 million by 20.30 percent. This is a 104.49 percent increase over sales of $41.42 million the same period last year.